Study · Randomized controlled trial · 2014

15 results

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A

European journal of endocrinology7 Feb 2014Cited by 124 (Europe PMC)

PMID24362411PMCIDPMC3922503DOI10.1530/eje-13-0797PepBankPUB-24362411

Summary

ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin.MethodsA total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study. They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted. The primary outcome was change in body weight.ResultsThirty six patients (aged 31.3 ± 7.1 years, BMI 37.1 ± 4.6 kg/m²) completed the study: 14 on MET, 11 on LIRA, and 11 on combined treatment. COMBI therapy was superior to LIRA and MET monotherapy in reducing weight, BMI, and waist circumference. Subjects treated with COMBI lost on average 6.5 ± 2.8 kg compared with a 3.8 ± 3.7 kg loss in the LIRA group and a 1.2 ± 1.4 kg loss in the MET group (P<0.001). The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively. BMI decreased by 2.4 ± 1.0 in the COMBI arm compared with 1.3 ± 1.3 in LIRA and 0.5 ± 0.5 in the MET arm (P<0.001). Waist circumference also decreased by 5.5 ± 3.8 cm in the COMBI arm compared with 3.2 ± 2.9 cm in LIRA and 1.6 ± 2.9 cm in the MET arm (P=0.029). Subjects treated with liraglutide experienced more nausea than those treated with metformin, but severity of nausea decreased over time and did not correlate with weight loss.ConclusionsShort-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study15

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS and poor response to metformin, liraglutide alone gave a 3.8 kg weight loss versus 1.2 kg with metformin (P<0.001 across the three arms).
In plain wordsIn obese women with PCOS, liraglutide alone led to more weight loss (3.8 kg) than metformin alone (1.2 kg) over 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseWeight change, liraglutide alone
Study
n: not reported in source
Comparator
Metformin
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Weight loss
3.8 kg
liraglutide
Weight loss
1.2 kg
metformin
Source sentences
Summary
Subjects treated with COMBI lost on average 6.5 ± 2.8 kg compared with a 3.8 ± 3.7 kg loss in the LIRA group and a 1.2 ± 1.4 kg loss in the MET group (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241101
02HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS and poor response to metformin, adding liraglutide to metformin gave a 6.5 kg weight loss versus 1.2 kg with metformin alone (P<0.001 across the three arms).
In plain wordsIn obese women with PCOS, adding liraglutide to metformin led to more weight loss (6.5 kg) than metformin alone (1.2 kg) over 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseWeight change, combination versus metformin
Study
n: not reported in source
Comparator
Metformin
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Weight loss
6.5 kg
combined
Weight loss
1.2 kg
metformin
Source sentences
Summary
Subjects treated with COMBI lost on average 6.5 ± 2.8 kg compared with a 3.8 ± 3.7 kg loss in the LIRA group and a 1.2 ± 1.4 kg loss in the MET group (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241102
03HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, 38% of all subjects were high responders who lost 5% or more of body weight; the liraglutide arm accounted for 16% and the metformin arm for 0%.
In plain wordsIn obese women with PCOS, 16% of all subjects were high weight-loss responders in the liraglutide-alone arm, and 0% in the metformin arm.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of 5% or more, liraglutide alone
Study
n: not reported in source
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
High responders (>=5% weight loss), share of all subjects
16%
liraglutide arm
High responders (>=5% weight loss), share of all subjects
0%
metformin arm
Source sentences
Summary
The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241104
04HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, 38% of all subjects were high responders who lost 5% or more of body weight; the combined liraglutide and metformin arm accounted for 22% and the metformin arm for 0%.
In plain wordsIn obese women with PCOS, 22% of all subjects were high weight-loss responders in the liraglutide-plus-metformin arm, and 0% in the metformin-alone arm.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of 5% or more, combination versus metformin
Study
n: not reported in source
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
High responders (>=5% weight loss), share of all subjects
22%
combined arm
High responders (>=5% weight loss), share of all subjects
0%
metformin arm
Source sentences
Summary
The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241105
05HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, BMI fell by 1.3 with liraglutide alone versus 0.5 with metformin (P<0.001 across the three arms).
In plain wordsIn obese women with PCOS, BMI fell more with liraglutide alone than with metformin alone.
Peptide
Liraglutide
Outcome
DecreaseBMI change, liraglutide alone
Study
n: not reported in source
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
BMI decrease
1.3 kg/m2
liraglutide
BMI decrease
0.5 kg/m2
metformin
Source sentences
Summary
BMI decreased by 2.4 ± 1.0 in the COMBI arm compared with 1.3 ± 1.3 in LIRA and 0.5 ± 0.5 in the MET arm (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241107
06HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, BMI fell by 2.4 with liraglutide plus metformin versus 0.5 with metformin alone (P<0.001 across the three arms).
In plain wordsIn obese women with PCOS, BMI fell more with liraglutide added to metformin than with metformin alone.
Peptide
Liraglutide
Outcome
DecreaseBMI change, combination versus metformin
Study
n: not reported in source
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
BMI decrease
2.4 kg/m2
combined
BMI decrease
0.5 kg/m2
metformin
Source sentences
Summary
BMI decreased by 2.4 ± 1.0 in the COMBI arm compared with 1.3 ± 1.3 in LIRA and 0.5 ± 0.5 in the MET arm (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241108
07HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, waist circumference fell by 3.2 cm with liraglutide alone versus 1.6 cm with metformin (P=0.029 across the three arms).
In plain wordsIn obese women with PCOS, waist size fell more with liraglutide alone than with metformin alone.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference change, liraglutide alone
Study
n: not reported in source
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Waist circumference decrease
3.2 cm
liraglutide
Waist circumference decrease
1.6 cm
metformin
Source sentences
Summary
Waist circumference also decreased by 5.5 ± 3.8 cm in the COMBI arm compared with 3.2 ± 2.9 cm in LIRA and 1.6 ± 2.9 cm in the MET arm (P=0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241110
08HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, waist circumference fell by 5.5 cm with liraglutide plus metformin versus 1.6 cm with metformin alone (P=0.029 across the three arms).
In plain wordsIn obese women with PCOS, waist size fell more with liraglutide added to metformin than with metformin alone.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference change, combination versus metformin
Study
n: not reported in source
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Waist circumference decrease
5.5 cm
combined
Waist circumference decrease
1.6 cm
metformin
Source sentences
Summary
Waist circumference also decreased by 5.5 ± 3.8 cm in the COMBI arm compared with 3.2 ± 2.9 cm in LIRA and 1.6 ± 2.9 cm in the MET arm (P=0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241111
09HumanRandomized controlled trialSafety outcome
In obese women with PCOS, subjects treated with liraglutide experienced more nausea than those treated with metformin.
In plain wordsIn obese women with PCOS, nausea was more common with liraglutide than with metformin.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Metformin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Subjects treated with liraglutide experienced more nausea than those treated with metformin
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241113
10HumanRandomized controlled trialSafety outcome
In obese women with PCOS treated with liraglutide, the severity of nausea decreased over time.
In plain wordsIn obese women with PCOS taking liraglutide, nausea became less severe over time.
Peptide
Liraglutide
Outcome
DecreaseNausea severity over time
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
but severity of nausea decreased over time and did not correlate with weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241114
11HumanRandomized controlled trialSafety outcome
In obese women with PCOS treated with liraglutide, nausea severity did not correlate with weight loss.
In plain wordsIn obese women with PCOS taking liraglutide, how bad the nausea was did not match how much weight was lost.
Peptide
Liraglutide
Outcome
No significant changeCorrelation of nausea severity with weight loss
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
but severity of nausea decreased over time and did not correlate with weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
Show in the study text Report a problemFND-2436241115

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS and poor response to metformin, the combination of liraglutide and metformin gave a 6.5 kg weight loss versus 3.8 kg with liraglutide alone (P<0.001 across the three arms).
In plain wordsIn obese women with PCOS, liraglutide plus metformin led to more weight loss (6.5 kg) than liraglutide alone (3.8 kg).
Peptide
Liraglutide
Outcome
DecreaseWeight change, combination versus liraglutide alone
Study
n: not reported in source
Comparator
Liraglutide
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
6.5 kg
combined
Weight loss
3.8 kg
liraglutide
Source sentences
Summary
Subjects treated with COMBI lost on average 6.5 ± 2.8 kg compared with a 3.8 ± 3.7 kg loss in the LIRA group and a 1.2 ± 1.4 kg loss in the MET group (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2436241103
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS, 38% of all subjects were high responders who lost 5% or more of body weight; the combined liraglutide and metformin arm accounted for 22% and the liraglutide arm for 16%.
In plain wordsIn obese women with PCOS, 22% of all subjects were high weight-loss responders in the liraglutide-plus-metformin arm, and 16% in the liraglutide-alone arm.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of 5% or more, combination versus liraglutide alone
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Measurements
High responders (>=5% weight loss), share of all subjects
22%
combined arm
High responders (>=5% weight loss), share of all subjects
16%
liraglutide arm
Source sentences
Summary
The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2436241106
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS, BMI fell by 2.4 with liraglutide plus metformin versus 1.3 with liraglutide alone (P<0.001 across the three arms).
In plain wordsIn obese women with PCOS, BMI fell more with liraglutide plus metformin than with liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseBMI change, combination versus liraglutide alone
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Measurements
BMI decrease
2.4 kg/m2
combined
BMI decrease
1.3 kg/m2
liraglutide
Source sentences
Summary
BMI decreased by 2.4 ± 1.0 in the COMBI arm compared with 1.3 ± 1.3 in LIRA and 0.5 ± 0.5 in the MET arm (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2436241109
15HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS, waist circumference fell by 5.5 cm with liraglutide plus metformin versus 3.2 cm with liraglutide alone (P=0.029 across the three arms).
In plain wordsIn obese women with PCOS, waist size fell more with liraglutide plus metformin than with liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference change, combination versus liraglutide alone
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Measurements
Waist circumference decrease
5.5 cm
combined
Waist circumference decrease
3.2 cm
liraglutide
Source sentences
Summary
Waist circumference also decreased by 5.5 ± 3.8 cm in the COMBI arm compared with 3.2 ± 2.9 cm in LIRA and 1.6 ± 2.9 cm in the MET arm (P=0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study.
Summary · context
They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2436241112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials5

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

5 trials · 3 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT05952882

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Mỹ Đức Hospitaln = 188est. 1 Nov 2023 to est. 31 Dec 2025

Polycystic Ovary Syndrome · Obesity · Infertility, Female

Trial page ClinicalTrials.govUpdated 23 Oct 2023

Status unknownPhase 4NCT05702905

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Peking University First Hospitaln = 759 May 2023 to est. 30 Jun 2025

PCOS (Polycystic Ovary Syndrome) · Semaglutide

Trial page ClinicalTrials.govUpdated 25 Mar 2024

CompletedPhase 4NCT03352869

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

RenJi Hospitaln = 18328 Nov 2017 to 31 Jul 2018

Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

Trial page ClinicalTrials.govUpdated 11 Sept 2019

CompletedPhase 4NCT03353948

The Effect of a Liraglutide on IVF in Obese PCOS

University Medical Centre Ljubljanan = 301 Sept 2014 to 1 Sept 2016

Polycystic Ovary Syndrome · Obesity · Infertility, Female

Trial page ClinicalTrials.govUpdated 27 Nov 2017

CompletedPhase 4NCT03034941

Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients

University Medical Centre Ljubljanan = 35Apr 2014 to Dec 2016

Obesity · PCOS

Trial page ClinicalTrials.govUpdated 27 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.